| Efficacy and safety of sirolimus in the treatment of complicated vascular anomalies DM Adams, CC Trenor, AM Hammill, AA Vinks, MN Patel, G Chaudry, ... Pediatrics 137 (2), 2016 | 810 | 2016 |
| Activity of selumetinib in neurofibromatosis type 1–related plexiform neurofibromas E Dombi, A Baldwin, LJ Marcus, MJ Fisher, B Weiss, AR Kim, P Whitcomb, ... New England Journal of Medicine 375 (26), 2550-2560, 2016 | 697 | 2016 |
| Selumetinib in children with inoperable plexiform neurofibromas AM Gross, PL Wolters, E Dombi, A Baldwin, P Whitcomb, MJ Fisher, ... New England Journal of Medicine 382 (15), 1430-1442, 2020 | 587 | 2020 |
| Juvenile myelomonocytic leukemia: a report from the 2nd International JMML Symposium RJ Chan, T Cooper, CP Kratz, B Weiss, ML Loh Leukemia research 33 (3), 355-362, 2009 | 192 | 2009 |
| MIBG in neuroblastoma diagnostic imaging and therapy SE Sharp, AT Trout, BD Weiss, MJ Gelfand Radiographics 36 (1), 258-278, 2016 | 181 | 2016 |
| Hyperactive Ras as a therapeutic target in neurofibromatosis type 1 B Weiss, G Bollag, K Shannon American journal of medical genetics 89 (1), 14-22, 1999 | 177 | 1999 |
| Sirolimus for progressive neurofibromatosis type 1–associated plexiform neurofibromas: a Neurofibromatosis Clinical Trials Consortium phase II study B Weiss, BC Widemann, P Wolters, E Dombi, A Vinks, A Cantor, ... Neuro-oncology 17 (4), 596-603, 2015 | 159 | 2015 |
| Enrichment of targetable mutations in the relapsed neuroblastoma genome OM Padovan-Merhar, P Raman, I Ostrovnaya, K Kalletla, KR Rubnitz, ... PLoS genetics 12 (12), e1006501, 2016 | 137 | 2016 |
| NF106: a neurofibromatosis clinical trials consortium phase II trial of the MEK inhibitor mirdametinib (PD-0325901) in adolescents and adults with NF1-related plexiform … BD Weiss, PL Wolters, SR Plotkin, BC Widemann, JH Tonsgard, ... Journal of Clinical Oncology 39 (7), 797-806, 2021 | 107 | 2021 |
| Management of neurofibromatosis type 1-associated plexiform neurofibromas MJ Fisher, JO Blakeley, BD Weiss, E Dombi, S Ahlawat, S Akshintala, ... Neuro-oncology 24 (11), 1827-1844, 2022 | 106 | 2022 |
| 131I-metaiodobenzylguanidine with intensive chemotherapy and autologous stem cell transplantation for high-risk neuroblastoma. A new approaches to neuroblastoma therapy (NANT … GA Yanik, JG Villablanca, JM Maris, B Weiss, S Groshen, A Marachelian, ... Biology of Blood and Marrow Transplantation 21 (4), 673-681, 2015 | 103 | 2015 |
| Sirolimus for non‐progressive NF1‐associated plexiform neurofibromas: an NF clinical trials consortium phase II study B Weiss, BC Widemann, P Wolters, E Dombi, AA Vinks, A Cantor, B Korf, ... Pediatric blood & cancer 61 (6), 982-986, 2014 | 98 | 2014 |
| A team-based approach to reducing cardiac monitor alarms CE Dandoy, SM Davies, L Flesch, M Hayward, C Koons, K Coleman, ... Pediatrics 134 (6), e1686-e1694, 2014 | 97 | 2014 |
| Secondary myelodysplastic syndrome and leukemia following 131I-metaiodobenzylguanidine therapy for relapsed neuroblastoma B Weiss, A Vora, J Huberty, RA Hawkins, KK Matthay Journal of pediatric hematology/oncology 25 (7), 543-547, 2003 | 94 | 2003 |
| Phase II trial of alisertib in combination with irinotecan and temozolomide for patients with relapsed or refractory neuroblastoma SG DuBois, YP Mosse, E Fox, RA Kudgus, JM Reid, R McGovern, ... Clinical Cancer Research 24 (24), 6142-6149, 2018 | 89 | 2018 |
| Anti-GD2 CAR-NKT cells in relapsed or refractory neuroblastoma: updated phase 1 trial interim results A Heczey, X Xu, AN Courtney, G Tian, GA Barragan, L Guo, CM Amador, ... Nature Medicine 29 (6), 1379-1388, 2023 | 87 | 2023 |
| Phase 1/1B trial to assess the activity of entrectinib in children and adolescents with recurrent or refractory solid tumors including central nervous system (CNS) tumors GW Robinson, AJ Gajjar, KM Gauvain, EM Basu, ME Macy, LD Maese, ... J Clin Oncol 37 (15_suppl), 10009, 2019 | 83 | 2019 |
| Phase I Study of Vorinostat as a Radiation Sensitizer with 131I-Metaiodobenzylguanidine (131I-MIBG) for Patients with Relapsed or Refractory Neuroblastoma SG DuBois, S Groshen, JR Park, DA Haas-Kogan, X Yang, E Geier, ... Clinical Cancer Research 21 (12), 2715-2721, 2015 | 80 | 2015 |
| Pilot study of vincristine, oral irinotecan, and temozolomide (VOIT regimen) combined with bevacizumab in pediatric patients with recurrent solid tumors or brain tumors L Wagner, B Turpin, R Nagarajan, B Weiss, T Cripe, J Geller Pediatric blood & cancer 60 (9), 1447-1451, 2013 | 79 | 2013 |
| Entrectinib in children and young adults with solid or primary CNS tumors harboring NTRK, ROS1, or ALK aberrations (STARTRK-NG) AV Desai, GW Robinson, K Gauvain, EM Basu, ME Macy, L Maese, ... Neuro-oncology 24 (10), 1776-1789, 2022 | 77 | 2022 |
